These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7691462)

  • 21. Taxol: an important new drug in the management of epithelial ovarian cancer.
    Markman M
    Yale J Biol Med; 1991; 64(6):583-90. PubMed ID: 1687343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel-containing combination chemotherapy for metastatic breast cancer.
    Hortobagyi GN; Ibrahim N
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):53-7. PubMed ID: 8629039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
    Hawkins MJ
    Oncology (Williston Park); 1992 Dec; 6(12):17-23; discussion 27-30. PubMed ID: 1361358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
    Duska LR; Penson R; Supko JG; Finkelstein DM; Makastorsis T; Gallagher J; Borden K; Goodman A; Fuller AF; Nikrui N; Seiden MV
    Clin Cancer Res; 1999 Jun; 5(6):1299-305. PubMed ID: 10389912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
    Meden H; Rath W; Kuhn W
    Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):187-93. PubMed ID: 7912212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promising new developments in the systemic treatment of ovarian cancer.
    Reed E
    J Assoc Acad Minor Phys; 1994; 5(1):16-21. PubMed ID: 7513218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel (Taxol®): A new natural product with major anticancer activity.
    De Furia MD
    Phytomedicine; 1997 Sep; 4(3):273-82. PubMed ID: 23195489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taxol reactions.
    Price KS; Castells MC
    Allergy Asthma Proc; 2002; 23(3):205-8. PubMed ID: 12125509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on the antitumor activity of paclitaxel in clinical trials.
    Rowinsky EK
    Ann Pharmacother; 1994 May; 28(5 Suppl):S18-22. PubMed ID: 7915154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Taxol (paclitaxel): future directions.
    Arbuck SG
    Ann Oncol; 1994; 5 Suppl 6():S59-62. PubMed ID: 7865437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.